Palladio Biosciences welcomes Alex Martin as CEO alongside Dr Lorenzo Pellegrini stepping to COO

– USA, PA –  Palladio Biosciences, Inc. a privately-owned, clinical-stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the appointment of Alex Martin as the company’s CEO.

Sandy Zweifach, Chairman of Palladio, also commented, “Alex has a great track record of executing strategy, building teams, and raising capital. We are very pleased he is joining Palladio at this exciting time.”

“I am very excited to welcome Alex to Palladio as CEO. I’ve known him for several years and believe his leadership and public company experience will be incredibly valuable to us as we take lixivaptan into Phase III and beyond. I look forward to helping Alex build Palladio into a leading biopharmaceutical company focused on orphan nephrology medicines,” said Lorenzo Pellegrini, Ph.D., founding CEO who will continue on as Chief Operating Officer.

About Alex Martin

Mr. Martin brings to Palladio over 25 years of experience in senior executive roles in the life sciences industry, with a focus on business development, operations, and raising capital. He was previously CEO of Realm Therapeutics which was acquired by ESSA Pharma in July 2019, and prior to that held executive roles at several biopharmaceutical companies including Intercept Pharmaceuticals where he was COO and BioXell where he was CFO. He began his career at SmithKline Beecham and later became Vice President, Business Development & Licensing at Novartis.

“I am delighted to come on board,” added Mr. Martin, “I look forward to continuing the great work already done developing lixivaptan for ADPKD and helping make this drug available to patients with orphan diseases of the kidney who currently have very limited options.”

Mr. Martin received his BA from Cornell University and an MBA from Harvard

About Palladio Biosciences, Inc.

Palladio Biosciences is a privately-owned, clinical-stage biopharmaceutical company developing medicines for orphan diseases of the kidney and is located near Philadelphia, PA. Palladio is initially developing its lead drug, lixivaptan, for Polycystic Kidney Disease, an orphan kidney disease for which there are limited treatment options.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.